Wenwen Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wenwen Liu has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Yuping Xu
Reproductive Medicine Center, Department of Obstetrics and Gynecology, The First Affiliated Hospital of Anhui Medical University, Hefei, China
2 shared publications Bing Han
Department of Obstetrics and Gynecology, the First Affiliated Hospital of Anhui Medical University, No 218 Jixi Road, Hefei, Anhui 230022, China; NHC Key Laboratory of Study on Abnormal Gametes and Reproductive Tract, Anhui Medical University, No 81 Meishan Road, Hefei, Anhui 230032, China; School of Public Health, Anhui Medical University, No 81 Meishan Road, Hefei, Anhui 230032, China
1 shared publication- Bing Han
Department of Obstetrics and Gynecology, the First Affiliated Hospital of Anhui Medical University, Hefei, China
1 shared publication Guanxiong Wang
Department of Obstetrics and Gynecology, the First Affiliated Hospital of Anhui Medical University, No 218 Jixi Road, Hefei, Anhui 230022, China; NHC Key Laboratory of Study on Abnormal Gametes and Reproductive Tract, Anhui Medical University, No 81 Meishan Road, Hefei, Anhui 230032, China; School of Public Health, Anhui Medical University, No 81 Meishan Road, Hefei, Anhui 230032, China
1 shared publicationHui Lu
Department of Clinical Laboratory, the Second Affiliated Hospital of Anhui Medical University
1 shared publication- Hui Lu
Department of Clinical Laboratory, the Second Affiliated Hospital of Anhui Medical University, Hefei, China
1 shared publication
Latest Publications
- Open Access
- 26 August 2026
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 83 (1)
ATF4 contributes to proper maintenance of BTB-associated junctional organization under stress conditions in sertoli cells of mice
- 26 August 2026
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 83 (1)
Open AccessATF4 contributes to proper maintenance of BTB-associated junctional organization under stress conditions in sertoli cells of mice
- Open Access
- 21 August 2026
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 323, 120668
Tetrachloro-1,4-benzoquinone disrupts oocyte quality through mitochondrial dysfunction and oxidative stress
- 21 August 2026
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 323, 120668
Open AccessTetrachloro-1,4-benzoquinone disrupts oocyte quality through mitochondrial dysfunction and oxidative stress
- Open Access
- 12 February 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1738116
Association between peripheral IFN-γ+ cytotoxic lymphocytes and response to PD-1/PD-L1-based therapy in hepatocellular carcinoma
Background: Programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1)-based immune checkpoint therapy (ICT), either alone or in combination with tyrosine kinase inhibitors (TKIs) or bevacizumab, benefits a subset of patients with hepatocellular carcinoma (HCC), and reliable predictive biomarkers remain limited. Methods: Between August 2024 and July 2025, 55 HCC patients treated with PD-1-based therapies were included. Objective response rate (ORR) was assessed according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST). Peripheral cytotoxic lymphocyte subsets and effector functions were profiled by multiparameter flow cytometry. Results: We observed that the ICT plus TKI group exhibited a higher ORR than ICT monotherapy (54.5% vs. 29.4%; n = 22 vs. n = 17), whereas the ORR in the ICT plus bevacizumab group was comparable to ICT monotherapy (37.5% vs. 29.4%; n = 16 vs. n = 17). Compared with ICT monotherapy, patients receiving ICT plus TKI therapy had higher peripheral CD8 ⁺ cytotoxic T lymphocyte (CTL) proportions and elevated percentages of IFN-γ + CTLs, natural killer (NK) cells, and natural killer T (NKT) cells (all P < 0.05). Across all treatment regimens, IFN-γ + cytotoxic lymphocytes frequencies were associated with treatment response and showed good discrimination, whereas circulating serum IFN-γ levels were not informative. Conclusion: These findings support peripheral IFN-γ + cytotoxic lymphocytes as a candidate noninvasive biomarker for stratifying HCC patients receiving PD-1/PD-L1-based therapy.
- 12 February 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1738116
Open AccessAssociation between peripheral IFN-γ+ cytotoxic lymphocytes and response to PD-1/PD-L1-based therapy in hepatocellular carcinoma
Background: Programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1)-based immune checkpoint therapy (ICT), either alone or in combination with tyrosine kinase inhibitors (TKIs) or bevacizumab, benefits a subset of patients with hepatocellular carcinoma (HCC), and reliable predictive biomarkers remain limited. Methods: Between August 2024 and July 2025, 55 HCC patients treated with PD-1-based therapies were included. Objective response rate (ORR) was assessed according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST). Peripheral cytotoxic lymphocyte subsets and effector functions were profiled by multiparameter flow cytometry. Results: We observed that the ICT plus TKI group exhibited a higher ORR than ICT monotherapy (54.5% vs. 29.4%; n = 22 vs. n = 17), whereas the ORR in the ICT plus bevacizumab group was comparable to ICT monotherapy (37.5% vs. 29.4%; n = 16 vs. n = 17). Compared with ICT monotherapy, patients receiving ICT plus TKI therapy had higher peripheral CD8 ⁺ cytotoxic T lymphocyte (CTL) proportions and elevated percentages of IFN-γ + CTLs, natural killer (NK) cells, and natural killer T (NKT) cells (all P < 0.05). Across all treatment regimens, IFN-γ + cytotoxic lymphocytes frequencies were associated with treatment response and showed good discrimination, whereas circulating serum IFN-γ levels were not informative. Conclusion: These findings support peripheral IFN-γ + cytotoxic lymphocytes as a candidate noninvasive biomarker for stratifying HCC patients receiving PD-1/PD-L1-based therapy.